Food and Drug Administration Center for Biologics Evaluation and Research (CBER)

143rd Vaccines and Related Biological Products Advisory Committee Meeting

May 11, 2016 Via Teleconference

Office of Vaccines Research and Review (OVRR)

Division of Bacterial, Parasitic, and Allergenic Products (DBPAP)

Laboratory of Bacterial Polysaccharides (LBP)

Building 31, Great Room, Salon C

Silver Spring, MD 20993

Live Webcast: https://collaboration.fda.gov/vrbpac0516/

DRAFT AGENDA

DRAFT AGENDA: Open Session

Time	Presentation/ Presenter
1:00 p.m.	Call to Order and Opening Remarks
	Kathryn Edwards, M.D., Chair
	Conflicts of Interest Statement
	Sujata Vijh, Ph.D., DFO
	Topic: Presentations of the Laboratory of Bacterial Polysaccharides, Division of Bacterial,
	Parasitic, and Allergenic Products, Office of Vaccines Research and Review, Center for
	Biologics Evaluation and Research
1:15 p.m.	Overview of CBER Research/Site Visit Process
	Carolyn Wilson, Ph.D.
	Associate Director for Research
	CBER, FDA
1:30 p.m.	Overview of OVRR
	Marion Gruber, Ph.D.
	Director
	OVRR, CBER, FDA
1:40 p.m.	Overview of DBPAP
	Jay Slater, M.D.
	Director
	LBP, CBER, FDA
1:50 p.m.	Overview of LBP
	Willie Vann, Ph.D.
	Laboratory Chief
	LBP, CBER, FDA
2:15 p.m.	Questions
2:25 p.m.	Open Public Hearing (if no speakers, will move directly to closed session)
3:25 p.m.	Closed Session
4:30 p.m.	Adjournment